Upgrade to SI Premium - Free Trial

Pfizer (PFE) Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI, MEKTOVI and Cetuximab for Treatment of BRAFV600E-mCRC

September 30, 2019 6:22 AM
Pfizer Inc. (NYSE: PFE) today announced detailed results from the interim analysis of the Phase 3 BEACON CRC trial evaluating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles